1. Scrip
  2. >>Business

Chugai appoints new US CMO

 
• By Lucie Ellis-Taitt

Chugai Pharma USA (CPUSA) a wholly owned subsidiary of Chugai Pharmaceutical, a Tokyo, Japan-based member of the Roche Group, has named Dr Athos Gianella-Borradori chief medical officer, CPUSA. Dr Gianella-Borradori has more than 20 years' experience in international drug research. His prior roles include senior positions in research and development at Novartis (Switzerland), Crucell (The Netherlands), Bavarian Nordic (Germany), Cyclacel (United Kingdom), Merck Serono (Switzerland) and Clavis Pharma (Norway). 

Chugai Pharma USA (CPUSA) a wholly owned subsidiary of Chugai Pharmaceutical, a Tokyo, Japan-based member of the Roche Group, has named Dr Athos Gianella-Borradori chief medical officer, CPUSA. Dr Gianella-Borradori has more than 20 years' experience in international drug research. His prior roles include senior positions in research and development at Novartis (Switzerland), Crucell (The Netherlands), Bavarian Nordic (Germany), Cyclacel (United Kingdom), Merck Serono (Switzerland) and Clavis Pharma (Norway). 

Dr Gianella-Borradori, who earned his medical degree at the Swiss establishment the University of Bern, is also board certified in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Activist Investor Vs. Japan Pharma: ASKA Plans Poison Pill As Dalton Pushes For MBO

 
• By Lisa Takagi

While ASKA tries to double the number of its stocks to avoid MBO attempts by Dalton, the Asia-focused PE insists on the plan while criticising the move as irresponsible.

Finance Watch: Karyopharm Cuts Jobs In Cash Crunch; Pacira’s Layoffs Attributed To Efficiency

 
• By Mandy Jackson

Restructuring Edition: Karyopharm is reducing its workforce by 20% as it seeks alternatives to extend its cash runway, but Pacira’s production improvements created efficiency that necessitate an 8% layoff in manufacturing. Jasper, Century, Sage, Leap and Prothena also cut jobs.

Kailera Eyes Global Obesity Market With Hengrui’s Phase III Dual Agonist

 
• By Joseph Haas

With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.

China’s Mid-Cap Companies Thriving On Big Pharma Deals

 
• By Andrew McConaghie and Edwin Elmhirst

Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.

More from Scrip

China’s Mid-Cap Companies Thriving On Big Pharma Deals

 
• By Andrew McConaghie and Edwin Elmhirst

Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.

In Brief: Nanoscope Ploughs Forward With FDA Application For Retinitis Pigmentosa Gene Therapy

 
• By Manas Mishra

Nanoscope’s experimental gene therapy, MCO-010, is designed to target the broader retinitis pigmentosa population, regardless of the underlying gene mutation, with a completed US regulatory submission expected in early 2026.

Stock Watch: Pharma Financial Forecasts Cannot Withstand Headwinds Forever

 
• By Andy Smith

Pharma company financial guidance emerged largely unscathed from a first quarter punctured by a weakening US dollar and threats of import tariffs on drugs. With other pressures either already evident or on the horizon, guidance revisions may be unavoidable.